Alpha Synuclein Expressing Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Alpha-synuclein expressing neurons represent a critical population in the study of Parkinson's disease (PD) and related synucleinopathies. These neurons are characterized by the presence of alpha-synuclein (SNCA), a small presynaptic protein that plays essential roles in normal neuronal function but can aggregate into toxic species that drive neurodegeneration. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Synuclein Family | [4]
| Location | Presynaptic terminals, Lewy bodies | [5]
| Protein | Alpha-synuclein (SNCA) | [6]
| Function | Synaptic plasticity, neurotransmitter release | [7]
| Associated Diseases | Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0004117 | retinal ganglion cell A |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0004117 | retinal ganglion cell A | Medium |
Alpha-synuclein is highly enriched in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under normal conditions, alpha-synuclein:
The protein's N-terminal domain binds to lipid membranes, particularly those of synaptic vesicles, while its C-terminal domain exhibits chaperone-like activity that helps maintain synaptic protein homeostasis.
Alpha-synuclein participates in membrane curvature generation and vesicle dynamics through its lipid-binding N-terminal region. This function is essential for:
The C-terminal region of alpha-synuclein has molecular chaperone activity that helps target misfolded proteins for autophagy-mediated degradation. Normal alpha-synuclein function includes:
In Parkinson's disease and related disorders, alpha-synuclein undergoes a toxic conformational change:
The aggregation is seeded by existing pathological forms in a prion-like manner, where misfolded alpha-synuclein can template the conversion of normal protein into the pathogenic form.
Specific neuronal populations are particularly vulnerable to alpha-synuclein pathology:
Alpha-synuclein pathology drives neuronal death through multiple mechanisms:
Alpha-synuclein is expressed throughout the nervous system but shows variable levels:
While alpha-synuclein is primarily neuronal, it can also be expressed in:
Understanding alpha-synuclein expressing neurons has led to several therapeutic approaches:
Alpha-synuclein in cerebrospinal fluid and blood serves as a biomarker:
Transgenic mice: SNCA overexpression under various promoters
Knockin models: Humanized alpha-synuclein with mutations
Viral vector models: AAV-mediated SNCA overexpression
Substantia Nigra
Dopaminergic Neurons
Mitoc- Neuroinflammationn in PD
The study of Alpha Synuclein Expressing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cregg et al. Alpha-synuclein function in the synapse (2010). 2010. ↩︎
Burre et al. Alpha-synuclein in synaptic function (2018). 2018. ↩︎
Mahul-Mellier et al. The process of Lewy body formation (2020). 2020. ↩︎
Zhang et al. Alpha-synuclein aggregation mechanisms (2023). 2023. ↩︎
Pujols et al. Alpha-synuclein structure and aggregation (2022). 2022. ↩︎
Wong, K. & Krainc, D. Alpha-synuclein toxicity in neurons (2017). 2017. ↩︎
Braeuning, V. Alpha-synuclein and mitochondrial dysfunction (2023). 2023. ↩︎